{{Rsnum
|rsid=2289015
|Gene=ACOT11
|Chromosome=1
|position=54609389
|Orientation=minus
|GMAF=0.0877
|Gene_s=ACOT11,FAM151A
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 0.0 | 6.4 | 93.6
| HCB | 5.2 | 32.6 | 62.2
| JPT | 4.5 | 24.3 | 71.2
| YRI | 0.0 | 3.5 | 96.5
| ASW | 0.0 | 5.5 | 94.5
| CHB | 5.2 | 32.6 | 62.2
| CHD | 2.8 | 26.4 | 70.8
| GIH | 0.0 | 6.0 | 94.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 9.1 | 20.0 | 70.9
| MKK | 0.6 | 5.2 | 94.2
| TSI | 0.0 | 7.9 | 92.1
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2289015
|Name_s=
|Gene_s=ACOT11, FAM151A
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.05, combined P value= 1.74E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470165
}}

{{GET Evidence
|gene=FAM151A
|aa_change=Gly546Asp
|aa_change_short=G546D
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2289015
|overall_frequency_n=343
|overall_frequency_d=10758
|overall_frequency=0.0318832
|n_genomes=10
|n_genomes_annotated=0
|n_haplomes=10
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|pph2_score=0.625
|nblosum100=4
|autoscore=3
|webscore=N
|n_web_uneval=3
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}